Possible Role for Ipilimumab in Metastatic Bladder Cancer, Study Suggests
A tailored immunotherapy regimen using nivolumab (Opdivo) induction and “boosts” with nivolumab and high-dose ipilimumab (Yervoy) as second-line treatment for metastatic urothelial cancer was associated with higher response rates compared with historical controls, the phase II TITAN-TCC trial showed. Among 83 patients in the intention-to-treat (ITT) population, a confirmed investigator-assessed objective response occurred in 33% […]